A5038819015- CAR-T cell therapy research
- Advancements in Semiconductor Devices and Circuit Design
- Chronic Lymphocytic Leukemia Research
- Biosimilars and Bioanalytical Methods
- Multiple Myeloma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Integrated Circuits and Semiconductor Failure Analysis
- Nanowire Synthesis and Applications
- Viral Infectious Diseases and Gene Expression in Insects
- Chemotherapy-induced cardiotoxicity and mitigation
- Cancer Risks and Factors
- Quinazolinone synthesis and applications
- Immunodeficiency and Autoimmune Disorders
- Biomedical Ethics and Regulation
- Histone Deacetylase Inhibitors Research
- Neutropenia and Cancer Infections
- Acute Lymphoblastic Leukemia research
- Olfactory and Sensory Function Studies
- Meta-analysis and systematic reviews
- CNS Lymphoma Diagnosis and Treatment
- Renal Transplantation Outcomes and Treatments
- Peripheral Neuropathies and Disorders
- Photoreceptor and optogenetics research
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology
Vanderbilt University Medical Center
2020-2025
Washington University in St. Louis
2020
The Ohio State University
2013-2015
Howard Hughes Medical Institute
2011
Histone deacetylase inhibitors (HDACi) are active agents for peripheral T-cell lymphoma (PTCL). Anecdotally angioimmunoblastic (AITL) appears to respond better than PTCL-not otherwise specified (NOS) HDACi. The new World Health Organization classification shows that a subgroup of PTCL carries similarities in phenotype and gene expression profiling AITL, comparable T follicular helper (TFH) cells. disease might behave similarly AITL when treated with We analyzed 127 patients or PTCL-NOS HDACi...
Abstract The pivotal trials of axicabtagene ciloleucel (axi-cel) chimeric Antigen receptor (CAR-T) therapy and other CD19 CAR-Ts were mainly done in the inpatient setting. We conducted a single-center non-randomized open label prospective clinical trial (NCT05108805). Objective was to evaluate feasibility safety outpatient administration axi-cel for relapsed/refractory diffuse B cell lymphoma (R/R DLBCL) using continuous remote patient monitoring with wearable devices telemedicine. enrolled...
There are no comprehensive machine learning (ML) tools used by oncologists to assist with risk identification and referrals cardio-oncology. This study applies ML algorithms identify oncology patients at for cardiovascular disease cardio-oncology generate scores support quality of care.De-identified patient data were obtained from Vanderbilt University Medical Center. Patients breast, kidney, B-cell lymphoma cancers targeted. Additionally, the included who received immunotherapy drugs...
By Shakthi T Bhaskar, Bhagirathbhai Dholaria & 3 more. Since the first (CAR) T-cell product received FDA approval in 2017, studies have been completed that led to approvals of CAR T-cells treat a variety malignancies.
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of many patients with aggressive relapsed or refractory large B-cell lymphoma (LBCL). Treatment can be complicated by clinically evident cytokine release syndrome (CRS), which is characterized development fever, hypoxia, and hypotension, life-threatening. Most treated CAR-T cells develop CRS, thought to represent an immune phenomenon. It was previously unknown whether who did not CRS had reduced cell activity...
e19004 Background: Prolonged hypogammaglobulinemia is a common side effect of CD19 chimeric antigen receptor (CAR) T-cell therapy for B-NHL. Average infection rates 1 year (yr) post CAR-T are 44-53% (Kampouri, Tran Infect Dis 2023). Prophylactic IVIG typically dosed by weight; however, optimal dosing strategy remains unknown. We explored the efficacy reduced flat dose on and non-relapse mortality (NRM) CAR-T. Methods: B-NHL pts who received commercial from Nov 2017 to Mar 2023 at Vanderbilt...
7572 Background: Systemic AL amyloidosis can lead to progressive multi-organ dysfunction including advanced heart failure which may require orthotopic transplantation (OHT). Hematologic outcomes of post-OHT are not well described. Methods: We report for patients with cardiac involvement from Nov 2008 - Jun 2023 at Vanderbilt University Medical Center. response was graded per the ISA guidelines. Results: Fourteen pts underwent OHT whom 13 had lambda light chain disease. Three (21%) isolated...
7041 Background: Prolonged hematologic toxicity is a common side effect of chimeric antigen receptor T-cell (CART) therapy. The EHA/EBMT panel developed the late ICAHT grading which incorporates depth neutropenia after Day 30. Recently, early grade (D 0-30) was associated with infection (infx) and survival outcomes. Here, we evaluate impact on infx outcomes CD19 CART. Methods: We included two cohorts adult patients (pts) large B cell lymphoma (LBCL), mantle (MCL), follicular (FL) who...
Anaplastic lymphoma kinase-positive large B-cell (ALK+ LBCL) is known to be a rare and aggressive form of that relapses quickly after both conventional chemotherapy more targeted therapy. Lenalidomide an immunomodulator has shown safety efficacy in multiple myeloma also approved for use several types lymphoma. In the case described here, patient had significant partial response lenalidomide, which not previously been this type Given how difficult treat ALK+ LBCL is, further research...